• Explore /
  • Poster
  • / Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Abstract Video & Slides Poster

Authors

Ramaprasad Srinivasan

Ramaprasad Srinivasan

Center for Cancer Research, National Cancer Institute, Bethesda, MD

Ramaprasad Srinivasan , Frede Donskov , Othon Iliopoulos , Wendy Kimryn Rathmell , Vivek Narayan , Benjamin L. Maughan , Stephane Oudard , Tobias Else , Jodi K. Maranchie , Sarah Joanne Welsh , Ananya Roy , Yanfang Liu , Rodolfo F. Perini , W. Marston Linehan , Eric Jonasch

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT03401788

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4555)

DOI

10.1200/JCO.2021.39.15_suppl.4555

Abstract #

4555

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Othon Iliopoulos

First Author: Eric Jonasch

First Author: David F. McDermott

First Author: Junji Furuse